Presentation Resources:
J Addict Med. 2014 Sep-Oct;8(5):299-308. doi: 10.1097/ADM.0000000000000059.
Unobserved "home" induction onto buprenorphine.
Lee JD1, Vocci F, Fiellin DA A comparison of buprenorphine induction strategies: patient-centered home-based inductions versus standard-of-care office-based inductions.
https://pubmed.ncbi.nlm.nih.gov/25254667/
Cunningham CO, Giovanniello A, Li X, Kunins HV, Roose RJ, Sohler NL.
J Subst Abuse Treat. 2011 Jun;40(4):349-56. Statement of the American Society Of Addiction Medicine Consensus Panel on the use of buprenorphine in
office-based treatment of opioid addiction.
https://pubmed.ncbi.nlm.nih.gov/22042215/
Kraus ML, Alford DP, Kotz MM, Levounis P, Mandell TW, Meyer M, Salsitz EA, Wetterau N, Wyatt SA; American Society Of Addiction Medicine..
J Addict Med. 2011 Dec;5(4):254-63. doi:
Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. https://pubmed.ncbi.nlm.nih.gov/21403039/
Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH.
Arch Intern Med. 2011 Mar 14;171(5):425-31.
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
Mattick RP, Breen C, Kimber J, Davoli M.Cochrane Database Syst Rev. 2014
https://pubmed.ncbi.nlm.nih.gov/24500948/
NIDA (2016). Understanding Drug Abuse and Addiction: What Science Says. Retrieved January 2, 2017,from https://www.drugabuse.gov/understanding-drug-abuse-addiction-what-science-says
Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence.
Amato L, Minozzi S, Davoli M, Vecchi S.
Cochrane Database Syst Rev. 2011 Oct 5;(10):CD004147
https://pubmed.ncbi.nlm.nih.gov/21975742/
Lancet. 2003 Feb 22;361(9358):662-8.
1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.
Kakko J1, Svanborg KD, Kreek MJ, Heilig M.
https://pubmed.ncbi.nlm.nih.gov/12606177/
Am J Public Health. 2013 May;103(5):917-22. doi: 10.2105/AJPH.2012.301049. Epub 2013 Mar 14. Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995-2009. Schwartz RP1, Gryczynski J, O'Grady KE, Sharfstein JM, Warren G, Olsen Y, Mitchell SG, Jaffe JH https://pmc.ncbi.nlm.nih.gov/articles/PMC3670653/
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006140. doi: 10.1002/14651858.CD006140.pub2.
Sustained-release naltrexone for opioid dependence.
Lobmaier P1, Kornør H, Kunøe N, Bjørndal A https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD006140.pub2/full
N Engl J Med. 2016 Mar 31;374(13):1232-42. doi: 10.1056/NEJMoa1505409.
Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders.
Lee JD1, Friedmann PD1, Kinlock TW1, Nunes EV1, Boney TY1, Hoskinson RA Jr1, Wilson D1, McDonald R1, Rotrosen J1, Gourevitch MN1, Gordon M1,Fishman M1, Chen DT1, Bonnie RJ1, Cornish JW1, Murphy SM1, O'Brien CP1 https://pubmed.ncbi.nlm.nih.gov/27028913/
Lancet. 2011 Apr 30;377(9776):1506-13. doi: 10.1016/S0140-6736(11)60358-9.
Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled,multicentre randomised trial.
Krupitsky E1, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL.
https://pubmed.ncbi.nlm.nih.gov/21529928/
Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the
Massachusetts Collaborative Care Model in Community Health Centers.
LaBelle CT, Han SC, Bergeron A, Samet JH.
J Subst Abuse Treat. 2016 Jan;60:6-13. https://pubmed.ncbi.nlm.nih.gov/26233698/
Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience.
Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, Samet JH.
Arch Intern Med. 2011 Mar 14;171(5):425-31. https://pubmed.ncbi.nlm.nih.gov/21403039/
Prev Med. 2015 Nov;80:10-1. doi: 10.1016/j.ypmed.2015.04.002. Epub 2015 Apr 11.
Vermont responds to its opioid crisis.
Simpatico TA1 J Addict Med. 2016 Sep-Oct;10(5):300-8. doi: 10.1097/ADM.0000000000000223.
https://pubmed.ncbi.nlm.nih.gov/25869219/
Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists. Lim JK1, Bratberg JP, Davis CS, Green TC, Walley AY
https://pubmed.ncbi.nlm.nih.gov/27261669/